BRISBANE, Calif.--(BUSINESS WIRE)--XDx, a molecular diagnostic company based in Brisbane, California, announced today that it is restructuring its business. In response to current market conditions, XDx is reprioritizing its efforts and will increase its research, development and commercial activities in support of AlloMap® in the heart transplant market, while continuing selected activities in autoimmunity. The company will focus on maximizing the current market opportunity for the FDA cleared AlloMap product, restructure its internal development program and pursue external research collaborations in lupus, as well as suspend development activities in lung transplant.
As a result of the strategic restructuring, the company will realign the organization in support of these priorities, resulting in a reduction of 25 positions. XDx is also undertaking other cost saving measures in response to the tightening economic situation. All of these measures together are expected to accelerate achievement of profitability.
Pierre Cassigneul, XDx’s chief executive officer, commented, “The decision to restructure XDx is a difficult but necessary step given the current economic environment in which we are operating. We believe the steps we are taking to reprioritize our efforts and realign the organization will strengthen the company in the short run and position us for long-term success.”
AlloMap, XDx’s first commercial product, was launched through the company’s CLIA-certified laboratory in 2005 and received clearance from the FDA as the first real-time PCR-based IVDMIA in August 2008. AlloMap Molecular Expression Testing is an innovative non-invasive test that uses genomic technologies to help physicians in their overall management of heart transplant patients. AlloMap has been used on more than 5,000 patients at more than 70 centers in the U.S. and is increasingly incorporated as part of patient management protocols.
About XDx
Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring gene expression in a patient’s peripheral blood. This work is the basis for AlloMap Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the identification of the probability of acute cellular rejection for postcardiac transplant patient management.
Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other diseases that involve transplant rejection and the immune system. XDx’s noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.
About AlloMap
AlloMap Molecular Expression Testing is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
Contact:
Pure Communications Media: Andrea Johnston, 910-616-5858
Source: XDx
